Chemistry:Nialamide
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H18N4O2 |
| Molar mass | 298.346 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[1] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[2][3]
Side effects include agitation and insomnia, less frequently dry mouth, dizziness, blurred vision, and hypomania, and rarely leukopenia and hepatitis. As with other MAOIs, a hypertensive crisis can be triggered by co-ingestion of tyramine. It is metabolized into isoniazid, an anti-tuberculosis agent, and so is contraindicated in patients with tuberculosis. The recommended dosage range is 75 to 200 mg per day, with maintenance doses as low as 12.5 mg every other day.[4]
The antiatherogenic activity of nialamide was used to design pyridinolcarbamate.[5]
See also
References
- ↑ William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3. https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935.
- ↑ Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. 26 April 2012. pp. 138–. ISBN 978-1-4398-4567-7. https://books.google.com/books?id=AHA2g-qq6WwC&pg=PA138.
- ↑ Shorter, Edward (28 September 2008). Before Prozac: The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5. https://books.google.com/books?id=8VaYF8pIPxgC&pg=PA137.
- ↑ Council on Drugs (1971). AMA Drug Evaluations (Report). Chicago: American Medical Association. https://archive.org/details/amadrugevaluatio00coun. Retrieved April 5, 2021.
- ↑ "Hypolipidemic Agents". Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. 13. Springer Science & Business Media. 6 December 2012. 217–92. doi:10.1007/978-3-0348-7068-9_5. ISBN 9783642661907. https://books.google.com/books?id=a1bmCAAAQBAJ&pg=PA387. Retrieved 3 October 2017.
 |  |
